Skip to main content

Talk Bio

Search This Blog

Henlius to Showcase 12 Research Presentations at ESMO 2026, Including U.S. Bridging Study of Serplulimab and PoC of PD-L1 ADC HLX43 in Gastric Cancer (Summary Highlights)

on July 21, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Henlius plans to present 12 research abstracts at ESMO 2026, centered on its innovative assets serplulimab (anti‑PD‑1) and HLX43 (PD‑L1 ADC).

A key highlight is the U.S. bridging study of serplulimab in first‑line extensive‑stage small‑cell lung cancer (ES‑SCLC), designed to support a U.S. BLA submission with data readout targeted for ESMO 2026.

Another major highlight is proof‑of‑concept (PoC) data for the PD‑L1 antibody–drug conjugate HLX43 in gastric cancer, extending its broad‑spectrum anti‑tumor profile beyond earlier‑shown activity in NSCLC and esophageal cancer.

Sources:

Henlius Completes Patient Enrolment in the U.S. Bridging ...

[PDF] Henlius Biotech (2696 HK)

Henlius Debuts HLX43 Phase 2 ESCC Data at ASCO GI ...

Latest Results from Studies of Henlius'Serplulimab in Lung Cancer ...

Patient Enrolment Completed in the U.S. Bridging Study of Serplulimab in ES-SCLC

ASCO 2026 | Henlius to Disclose Key PFS Data of PD-L1 ...

Henlius Debuts Phase 2 Results for Its Broad Anti-tumor ...

Henlius Reports 2025 Results: Sustained Growth in Both Revenue ...

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG ...

Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司

Company Announcement - FT.com - Markets data

Fosun Pharma Presents Oncology Research at ASCO 2026

Henlius Biotech (2696 HK)

Henlius' Serplulimab Approved for Perioperative Gastric Cancer ...

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

bridging study concept ESMO Henlius HLX43 Immunotherapy Malignant neoplasm of stomach PD-L1 Serplulimab Small cell carcinoma of lung therapeutic autologous dendritic cells United States

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals announced on February 25, 2026, the appointment of Jorge Bartolome as Chief Executive Officer and Board member, succeeding co-founder Allen Cunningham who transitions to Chief Operating Officer. 1 2 Jorge Bartolome brings over 25 years of experience, including CEO of AreteiaTx, President of Janssen Canada, and senior roles at GSK generating $8 billion in sales. 1 2 Rivus focuses on oral therapies for MASH, obesity, and cardiometabolic diseases, with lead candidate HU6 (oral mitochondrial uncoupler) succeeding in three Phase 2 trials. 1 2 2026 plans include advancing HU6 in the AMPLIFY Phase 2 trial for MASH and initiating first clinical trial for RV-8451, an oral muscle-preserving GLP-1 for obesity. 1 2 Ian F. Smith, Co-Chair of the Board, highlighted Bartolome's expertise in late-stage development and commercialization as ideal for Rivus' growth. 1 2 Sources: 1. https://www.globenewswire.com/news-release/2026/02/25/3244576/0/en/Rivus-Pharmaceu...

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC